Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Corporate Update (May 2016)
11 slides from Chugai Pharmaceutical's corporate update, May 19, 2016
Slide 1: Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical
Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd. Executive Vice President of Research and Risk Management, Osaka University Yasushi Yagi 1
Slide 2: Pioneering University-Industry "Co-creation" at Osaka University
Pioneering University- Industry “Co-creation” at Osaka University A new type of university-industry University-Industry The 3 rd stage collaboration, at Osaka University = Co-creation of university- Comprehensive collaboration from the stage of industry Approach 1 basic research collaboration Approa
Slide 3: Introduction of a new Framework for University-Industry Collaboration at Osaka University
Introduction of a new Framework for University-Industry Collaboration at Osaka University Comprehensive university-industry collaboration from the basic research stage Joint research, Endowment Comprehensive commissioned/ contract research collaboration with private enterprise Disclosure of research
Slide 4: World Premier International Research Center (WPI) Initiative
World Premier International Research Center (WPI) Initiative Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan World Premier International Research Center (WPI) Initiative Nine centers established in Japan. IFReC established as an international center for immunology resear
Slide 5: Pioneering University-Industry "Co-creation" at Osaka University
Pioneering University- Industry “Co-creation” at Osaka University Research based on IFReC promising ideas researchers Individual collaboration Company A Support from Osaka University Company Individual collaboration B Support from MEXT Company （Competitive） Individual collaboration C External resear
Slide 6: University-Industry "Co-creation" from Basic Research at IFReC to Applied Research
University- Industry “Co-creation” from Basic Research at IFReC to Applied Research Research based on IFReC promising ideas researchers Individual collaboration Company A Support from Osaka University Individual collaboration Company B Support from MEXT Right of first refusal （Competitive） Chugai Ex
Slide 7: Outline of Comprehensive Collaboration with IFReC
Outline of Comprehensive Collaboration with IFReC CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President Yutaka Tanaka May 19, 2016
Slide 8: Global Trends in the R&D of Pharmaceutical & Medical Technology
Global Trends in the R&D of Pharmaceutical & Medical Technology Elucidation of Disease Sophistication of Pharmaceutical Mechanisms & Medical Technology Gene Analysis Biopharmaceutical Fast Antibody Technology, High‐ Gene Omics functionalization, Evolution of Expression Analysis Analysis Manufacturin
Slide 9: Chugai's Strategy for Drug Discovery: Technology-driven Approach
Chugai’s Strategy for Drug Discovery ～Technology‐driven Approach～ Next-generation (high functionalized) Antibodies Disease- Selection of Development causing proper Drug of Innovative Small molecule Drugs Molecule Discovery Drug Target Discovery Middle molecule Drugs Technology Antibody Academia Matc
Slide 10: Value from the Collaboration of IFReC & Chugai
Value from the Collaboration of IFReC & Chugai ~ Innovation created by the fusion of IFReC’s cutting‐edge Immunology research and Chugai’s Drug Discovery Technology ~ IFReC Chugai Great Source of Drug Drug Discovery Approach Discovery Seeds with the driven by Innovative world’s most advanced Technol
Slide 11: Framework of IFReC-Chugai Comprehensive Collaboration
Framework of IFReC‐Chugai Comprehensive Collaboration ～New academia‐industry alliance collaborating from the stage of autonomous basic research at IFReC～ IFReC • Uncontrolled Cutting-edge Immunology Research by IFReC Researchers Autonomous Comprehensive • Periodical Disclosure of Autonomous Research